血清胎盘碱性磷酸酶单克隆抗体检测在睾丸肿瘤监测中的应用
Monoclonal antibody assay of serum placental alkaline phosphatase in the monitoring of testicular tumours.
作者信息
Epenetos A A, Munro A J, Tucker D F, Gregory W, Duncan W, MacDougall R H, Faux M, Travers P, Bodmer W F
出版信息
Br J Cancer. 1985 May;51(5):641-4. doi: 10.1038/bjc.1985.96.
A monoclonal antibody (H17E2) recognising both placental alkaline phosphatase (PLAP) and testicular PLAP-like alkaline phosphatase was incorporated in a solid phase immunoassay. This was used to measure levels of PLAP in 257 sera from 148 patients with germ cell neoplasms of the testis. High levels of PLAP were found in all patients with active seminomas (mean 0.85 O.D.) compared to those in clinical remission (mean 0.20 O.D.) (P less than 0.0001). More importantly, changing levels of PLAP correlated with the course of disease in 79 samples from 33 patients with seminoma (P less than 0.0001). Elevated PLAP levels were also noted in patients in remission who were smokers (mean 0.32 O.D.) compared to non-smokers (mean 0.15 O.D.) (P less than 0.001). These data demonstrate that determination of PLAP levels using this sensitive immunoassay is an important new adjunct in the monitoring of the response to treatment in patients with seminoma.
一种可识别胎盘碱性磷酸酶（PLAP）和睾丸PLAP样碱性磷酸酶的单克隆抗体（H17E2）被用于固相免疫测定。该方法用于检测148例睾丸生殖细胞瘤患者的257份血清中的PLAP水平。与临床缓解期患者（平均光密度0.20）相比，所有活动性精原细胞瘤患者的PLAP水平均较高（平均光密度0.85）（P<0.0001）。更重要的是，33例精原细胞瘤患者的79份样本中，PLAP水平的变化与疾病进程相关（P<0.0001）。与不吸烟者（平均光密度0.15）相比，吸烟的缓解期患者的PLAP水平也有所升高（平均光密度0.32）（P<0.001）。这些数据表明，使用这种灵敏的免疫测定法测定PLAP水平是监测精原细胞瘤患者治疗反应的一项重要新辅助手段。
Zotero 插件